PMID- 32729092
OWN - NLM
STAT- MEDLINE
DCOM- 20210708
LR  - 20210708
IS  - 1559-0100 (Electronic)
IS  - 1355-008X (Linking)
VI  - 71
IP  - 2
DP  - 2021 Feb
TI  - Real-world experience of lenvatinib in patients with advanced anaplastic thyroid 
      cancer.
PG  - 427-433
LID - 10.1007/s12020-020-02425-y [doi]
AB  - PURPOSE: We aimed to evaluate the clinical efficacy and safety of lenvatinib in 
      patients with advanced anaplastic thyroid cancer (ATC) in real-world practice. 
      METHODS: This multicenter, retrospective cohort study included 14 patients with 
      advanced ATC who received lenvatinib. We evaluated the response rate according to 
      RECIST. RESULTS: Ten patients had de novo ATC, and lenvatinib was used as a 
      neoadjuvant treatment in eight patients. During a median follow-up of 6.7 months, 
      patients received lenvatinib at a median dose of 13 mg daily. Overall, four 
      patients (29%) showed partial response, nine (64%) had stable disease, and one 
      (7%) had progressive disease. Tumor burden was reduced in 13 patients (93%), and 
      the median best percent change from the baseline was -15.8%. The median 
      progression-free survival and overall survival were 5.7 months (95% confidence 
      interval [CI], 2.2-8.3) and 6.7 months (95% CI, 3.0-8.4), respectively. All 
      patients experienced adverse events (AEs). Most AEs were manageable but two 
      AEs-tracheal perforation, and pneumothorax and pneumomediastinum-were 
      life-threatening. One patient underwent flap surgery for reconstruction of their 
      tracheal perforation, and another died of pneumothorax and pneumomediastinum, 
      which seemed to be related to lenvatinib. CONCLUSIONS: In this multicenter 
      real-world study, lenvatinib demonstrated limited clinical activity in advanced 
      ATC. It effectively reduced the tumor burden but showed doubtful survival 
      benefit. Although most AEs were manageable, one fatal AE was related to rapid 
      tumor shrinkage. Further studies are needed to clarify the efficacy and optimal 
      dose of lenvatinib in patients with advanced ATC.
FAU - Kim, Mijin
AU  - Kim M
AD  - Department of Internal Medicine, Biomedical Research Institute, Pusan National 
      University Hospital, Busan, Republic of Korea.
FAU - Ahn, Jonghwa
AU  - Ahn J
AD  - Department of Internal Medicine, Asan Medical Center, University of Ulsan College 
      of Medicine, Seoul, Republic of Korea.
FAU - Song, Dong Eun
AU  - Song DE
AD  - Department of Pathology, Asan Medical Center, University of Ulsan College of 
      Medicine, Seoul, Republic of Korea.
FAU - Yoon, Jee Hee
AU  - Yoon JH
AD  - Department of Internal Medicine, Chonnam National University Hwasun Hospital, 
      Chonnam, Republic of Korea.
FAU - Kang, Ho-Cheol
AU  - Kang HC
AD  - Department of Internal Medicine, Chonnam National University Hwasun Hospital, 
      Chonnam, Republic of Korea.
FAU - Lim, Dong Jun
AU  - Lim DJ
AD  - Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, 
      The Catholic University of Korea, Seoul, Republic of Korea.
FAU - Kim, Won Gu
AU  - Kim WG
AD  - Department of Internal Medicine, Asan Medical Center, University of Ulsan College 
      of Medicine, Seoul, Republic of Korea.
FAU - Kim, Tae Yong
AU  - Kim TY
AD  - Department of Internal Medicine, Asan Medical Center, University of Ulsan College 
      of Medicine, Seoul, Republic of Korea.
FAU - Kim, Won Bae
AU  - Kim WB
AD  - Department of Internal Medicine, Asan Medical Center, University of Ulsan College 
      of Medicine, Seoul, Republic of Korea.
FAU - Shong, Young Kee
AU  - Shong YK
AD  - Department of Internal Medicine, Asan Medical Center, University of Ulsan College 
      of Medicine, Seoul, Republic of Korea.
FAU - Jeon, Min Ji
AU  - Jeon MJ
AD  - Department of Internal Medicine, Asan Medical Center, University of Ulsan College 
      of Medicine, Seoul, Republic of Korea. mj080332@gmail.com.
FAU - Kim, Bo Hyun
AU  - Kim BH
AD  - Department of Internal Medicine, Biomedical Research Institute, Pusan National 
      University Hospital, Busan, Republic of Korea. pons71@hanmail.net.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20200729
PL  - United States
TA  - Endocrine
JT  - Endocrine
JID - 9434444
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Phenylurea Compounds)
RN  - 0 (Quinolines)
RN  - EE083865G2 (lenvatinib)
SB  - IM
MH  - *Antineoplastic Agents/adverse effects
MH  - Humans
MH  - Phenylurea Compounds/adverse effects
MH  - *Quinolines/adverse effects
MH  - Retrospective Studies
MH  - *Thyroid Carcinoma, Anaplastic/drug therapy
MH  - *Thyroid Neoplasms/drug therapy
OTO - NOTNLM
OT  - Anaplastic thyroid cancer
OT  - Lenvatinib
OT  - Response rate
OT  - Survival
OT  - Toxicity
EDAT- 2020/07/31 06:00
MHDA- 2021/07/09 06:00
CRDT- 2020/07/31 06:00
PHST- 2020/04/30 00:00 [received]
PHST- 2020/07/13 00:00 [accepted]
PHST- 2020/07/31 06:00 [pubmed]
PHST- 2021/07/09 06:00 [medline]
PHST- 2020/07/31 06:00 [entrez]
AID - 10.1007/s12020-020-02425-y [pii]
AID - 10.1007/s12020-020-02425-y [doi]
PST - ppublish
SO  - Endocrine. 2021 Feb;71(2):427-433. doi: 10.1007/s12020-020-02425-y. Epub 2020 Jul 
      29.